Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis

Nephrology

Volumn 12, Issue 5, 2007, Pages 431-436

  Goh, Bak Leong ^a   Ong, Loke Meng ^b   Sivanandam, Sarojini ^c   Lim, Teck Onn ^c   Morad, Zaki ^c  

^a Serdang Hospital   (Malaysia)

^b Penang Adventist Hospital   (Malaysia)

^c HOSPITAL KUALA LUMPUR   (Malaysia)

Author keywords

Anemia; Biogeneric; Biosimilar; Chronic kidney disease; Epoetin; Follow on biologic

Indexed keywords

GENERIC DRUG; GEREPO; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ACUTE CHOLECYSTITIS; ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; ARTICLE; BACKACHE; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FERRITIN BLOOD LEVEL; FEVER; HEADACHE; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOTENSION; INFLUENZA; IRON STORAGE; LUNG EDEMA; MAJOR CLINICAL STUDY; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION; VOMITING;

ADULT; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; MALE; MIDDLE AGED; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 34548426486     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00831.x     Document Type: Article

References (28)

1. Eschbach JW. The anaemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989 35 : 134 48.
2. Evans RW, Rader B, Manninen DL, Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990 263 : 825 30.
3. Lowrie EG, Ling J, Lew NL, Yiu Y. The relative contribution of measured variables to death risk among hemodialysis patients. In : Friedman EA (ed.). Death on Hemodialysis: Preventable or Inevitable? Boston, MA : Kluwer Academic Publishers, 1994 121 41.
4. EBPG II Working Group. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol. Dial. Transplant. 2004 19 (Suppl 2 ii1 47.
5. NKF-K/DOQI clinical practice guidelines for anaemia of chronic kidney disease, update 2000. Am. J. Kidney Dis. 2001 37 (Suppl 1 S182 238.
6. United States Renal Data System 2003. Annual Data Report 2003. [Cited 15 Jan 2006.] Available from URL: http://www.usrds.org//pdf
7. Leese B, Hutton J, Maynard A. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries. Pharmacoeconomics 1992 1 : 346 56.
8. Greer JW, Milam RA, Eggers PW. Trends in use, cost and outcomes of recombinant human erythropoietin 1989-1998. Health Care Finance Rev. 1999 20 : 55 62.
9. Collins AJ. Anemia management prior to dialysis: Cardiovascular and cost-benefit observations. Nephrol. Dial. Transplant. 2003 18 (Suppl 2 ii2 6.
10. Valderrabano F, Horl WH, Jacobs C, McDougall IC. European survey on anaemia management (ESAM). Nephrol. Dial. Transplant. 2000 15 (Suppl 4 1 76.
11. Valderrabano F, Harl WH, Macdougall IC et al. Pre-dialysis survey on anaemia management. Nephrol. Dial. Transplant. 2003 18 : 89 100.
12. Locatelli F, Pisoni RL, Combe C et al. Anaemia in haemodialysis patients in five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Nephrol. Dial. Transplant. 2004 19 : 121 32.
13. Pisoni RL, Bragg-Gresham JL, Young EW et al. Anaemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am. J. Kidney Dis. 2004 44 : 94 111.
14. Lim YN, Lim TO (eds). 12th Report of the National Renal Registry 2004. Kuala Lumpur 2005. [Cited 15 Jan 2006.] Available from URL: http://www.msn.org. my/nrr/
15. Schellekens H. Biosimilar epoetins: How similar are they? Eur. J. Hosp. Pharm. 2004 3 : 43 7.
16. European Medicines Agency (EMEA). Committee for Medicinal Products for Human Use (CHMP/437/04) Guideline on Similar Biological Medicinal Products. London : EMEA, 2004.
17. European Medicines Agency (EMEA). Committee for Medicinal Products for Human Use (EMEA/CHMP/BWP/49348/2005) Guideline on Similar Biological Medicinal Products Containing Biotechnology Derived Proteins as Active Substance: Quality Issues. London : EMEA, 2005.
18. European Medicines Agency (EMEA). Committee for Medicinal Products for Human Use (EMEA/CHMP/94526/2005) Guidance on Biosimilar Medicinal Products Containing Recombinant Human Erythropoietins. London : EMEA, 2005.
19. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of combined phase I and II trials. N. Engl. J. Med. 1987 316 : 73 8.
20. Winearls CG, Oliver DO, Pippard MJ et al. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet 1986 2 : 1175 7.
21. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter trial. Ann. Intern. Med. 1989 111 : 992 1000.
22. Hwang IK, Morikawa T. Design issues in noninferiority/equivalence trials. Drug Inf. J. 1999 33 : 1205 18.
23. ICH Steering Committee. ICH Harmonized Tripartite Guideline, Statistical Principles for Clinical Trials. Final version, February 1998.
24. Lacson E, Ofsthun N, Lazarus JM. Effect of variability in Anemia management on hemoglobin outcomes in ESRD. Am. J. Kidney Dis. 2003 41 : 111 24.
25. Altman D, Bland M. Regression towards the mean. BMJ 1994 308 : 1499.
26. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the Evaluation of New Treatments. Ann. Intern. Med. 2000 133 : 455 63.
27. Hauck WW, Anderson S. Some issues in the design and analysis of equivalence trials. Drug Inf. J. 1999 33 : 109 18.
28. Garbe E, Rohmel J, Gundert-Remy U. Clinical and Statistical issues in therapeutic equivalence trials. Eur. J. Clin. Pharmacol. 1993 45 : 1 7.